E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10039632 |
E.1.2 | Term | Schizophrenia NOS |
E.1.2 | System Organ Class | 100000004873 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to provide PoC data to assess the effect on cognition of oral once daily administration of BI 425809 given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment and adjunctive CCT. |
|
E.2.2 | Secondary objectives of the trial |
Other objectives of this trial are to explore endpoints to assess functioning and well-being of patients with schizophrenia, and to evaluate safety and pharmacokinetics of BI 425809. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female patients who are 18-50 years (inclusive) of age at time of consent
2. Established schizophrenia DSM-5 with the following clinical features:
-Outpatient, with no hospitalization for worsening of schizophrenia within 3 months prior to randomization
-Psychiatrically stable without symptom exacerbation within 3 months prior to randomization
-PANSS score ≤ 5 on positive items P1, P3-P7 and ≤ 4 on positive item P2 at Visit 1, and confirmed at Visit 2
3. Patients must be on stable antipsychotic treatment; also, current antipsychotic medications and concomitant anticholinergics, antiepileptics, lithium and allowed antidepressants must meet the criteria below:
-Patients must take 1 and may take up to 2 antipsychotics (typical and/or atypical), except for clozapine
-Patients must be stable on current antipsychotics, anticholinergics, antiepileptics, lithium and allowed antidepressants for at least 3 months prior to randomization and be on current dose for at least 30 days prior to randomization
--Patients on long-acting injectable (LAI) antipsychotics should be on the same medication and dose for at least 3 months prior to randomization
4. Patients must demonstrate their ability to properly use the CCT device and program, as well as be compliant with CCT run-in
5. Patients must have a study partner who will preferably be consistent throughout the study
Further criteria apply. |
|
E.4 | Principal exclusion criteria |
1. Patients who have a categorical diagnosis of another current major psychiatric disorder on the M.I.N.I.
2. Patients with a history of participating in any formal cognitive remediation program for 10 or more training sessions
3. Patients who were treated with any of the following medications within the last 6 months prior to randomization:
-Bitopertin, BI 409306, encenicline or other investigational drug testing effects on cognition in schizophrenia
-Clozapine (atypical antipsychotic medication)
-Sarcosine, cycloserine, serine and glycine
-Stimulants (e.g. methylphenidate, dextroamphetamine, modafinil)
-Tricyclic antidepressants
4. Patients who have participated in a clinical trial with repeated assessments (i.e. a single assessment is not exclusionary) with the MCCB within the last 6 months prior to randomization
5. Significant history of drug abuse disorder within the last 6 months prior to informed consent, or a positive urine drug screen at Visit 1
6. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
Further criteria apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1) Change from baseline in neurocognitive function as measured by the neurocognitive composite score of the MCCB |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1) Change from baseline in cognitive function as measured by the overall MCCB composite score (including social cognition)
2) Change from baseline in the effect of cognitive deficit on day-to-day functioning as measured by SCoRS total score after 12 weeks of treatment
3) Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score
4) Percentage of patients with (S)AEs |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) 12 weeks
2) 12 weeks
3) 12 weeks
4) whole trial |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
New Zealand |
United States |
France |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 23 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 23 |